Form 6-K Sanofi For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq poised to lead Wall St after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Sanofi-Aventis (SNY) PT Raised to $60 at Argus
July 26, 2024 7:33 AM EDTArgus analyst Jasper Hellweg raised the price target on Sanofi-Aventis (NASDAQ: SNY) to $60.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "Our rating on Sanofi SA (NGS: SNY), a leading global pharmaceutical company, is BUY. We like Sanofis diverse range of businesses, which include branded pharmaceuticals, generics, vaccines, and consumer healthcare products. The... More
